KR102441934B1 - 간질환의 치료 또는 예방용 다공성 탄소 입자 - Google Patents

간질환의 치료 또는 예방용 다공성 탄소 입자 Download PDF

Info

Publication number
KR102441934B1
KR102441934B1 KR1020207022420A KR20207022420A KR102441934B1 KR 102441934 B1 KR102441934 B1 KR 102441934B1 KR 1020207022420 A KR1020207022420 A KR 1020207022420A KR 20207022420 A KR20207022420 A KR 20207022420A KR 102441934 B1 KR102441934 B1 KR 102441934B1
Authority
KR
South Korea
Prior art keywords
carbon
porous carbon
liver
carbon particles
liver disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207022420A
Other languages
English (en)
Korean (ko)
Other versions
KR20200096991A (ko
Inventor
캐롤 안젤라 호웰
세르게이 빅토르비치 미카로브스키
수잔 레이첼 샌드맨
라지브 잘란
제인 맥나우탄
Original Assignee
유씨엘 비즈니스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유씨엘 비즈니스 리미티드 filed Critical 유씨엘 비즈니스 리미티드
Publication of KR20200096991A publication Critical patent/KR20200096991A/ko
Application granted granted Critical
Publication of KR102441934B1 publication Critical patent/KR102441934B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/44—Elemental carbon, e.g. charcoal, carbon black
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B32/00—Carbon; Compounds thereof
    • C01B32/15—Nano-sized carbon materials
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2004/00—Particle morphology
    • C01P2004/60—Particles characterised by their size
    • C01P2004/64—Nanometer sized, i.e. from 1-100 nanometer
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2006/00—Physical properties of inorganic compounds
    • C01P2006/16—Pore diameter
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Materials Engineering (AREA)
  • Nanotechnology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Carbon And Carbon Compounds (AREA)
KR1020207022420A 2012-03-16 2013-03-15 간질환의 치료 또는 예방용 다공성 탄소 입자 Active KR102441934B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1204696.7A GB201204696D0 (en) 2012-03-16 2012-03-16 Therapy
GB1204696.7 2012-03-16
KR1020147029083A KR102142504B1 (ko) 2012-03-16 2013-03-15 간질환의 치료 또는 예방용 다공성 탄소 입자
PCT/GB2013/050673 WO2013136094A1 (en) 2012-03-16 2013-03-15 Porous carbon particles for use in the treatment or prevention of liver disease

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020147029083A Division KR102142504B1 (ko) 2012-03-16 2013-03-15 간질환의 치료 또는 예방용 다공성 탄소 입자

Publications (2)

Publication Number Publication Date
KR20200096991A KR20200096991A (ko) 2020-08-14
KR102441934B1 true KR102441934B1 (ko) 2022-09-08

Family

ID=46052080

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207022420A Active KR102441934B1 (ko) 2012-03-16 2013-03-15 간질환의 치료 또는 예방용 다공성 탄소 입자
KR1020147029083A Active KR102142504B1 (ko) 2012-03-16 2013-03-15 간질환의 치료 또는 예방용 다공성 탄소 입자

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020147029083A Active KR102142504B1 (ko) 2012-03-16 2013-03-15 간질환의 치료 또는 예방용 다공성 탄소 입자

Country Status (16)

Country Link
US (1) US9844568B2 (enExample)
EP (2) EP2825181B1 (enExample)
JP (2) JP6293680B2 (enExample)
KR (2) KR102441934B1 (enExample)
CN (1) CN104363916B (enExample)
AU (1) AU2013234099B2 (enExample)
BR (1) BR112014022810B1 (enExample)
DK (1) DK2825181T3 (enExample)
EA (1) EA038965B1 (enExample)
GB (1) GB201204696D0 (enExample)
IN (1) IN2014DN07637A (enExample)
MY (1) MY169093A (enExample)
NZ (1) NZ631429A (enExample)
SG (1) SG11201405771QA (enExample)
WO (1) WO2013136094A1 (enExample)
ZA (1) ZA201406989B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201204696D0 (en) * 2012-03-16 2012-05-02 Ucl Business Plc Therapy
ES2727153T3 (es) * 2014-04-17 2019-10-14 Immutrix Therapeutics Inc Composiciones de destoxificación terapéutica y métodos para la preparación y utilización de las mismas
TWI607765B (zh) * 2014-08-27 2017-12-11 Kureha Corp Adsorbents for oral administration, and nephropathy therapeutic agents and liver disease therapeutic agents
KR102328323B1 (ko) 2017-03-31 2021-11-19 엑시얼 테라퓨틱스, 인크. 자폐증 및 관련 장애의 치료 및 예방을 위한 장-선택적 봉쇄제
EP3476818A1 (en) 2017-10-27 2019-05-01 Heraeus Battery Technology GmbH A process for the preparation of a porous carbon material using an improved carbon source
EP3476817A1 (en) 2017-10-27 2019-05-01 Heraeus Battery Technology GmbH A process for the preparation of a porous carbon material using an improved amphiphilic species
WO2019131209A1 (ja) * 2017-12-27 2019-07-04 株式会社クラレ 活性炭およびその製法
JP7228498B2 (ja) * 2018-10-24 2023-02-24 フタムラ化学株式会社 フェノール樹脂の製造方法
WO2020085282A1 (ja) * 2018-10-24 2020-04-30 フタムラ化学株式会社 フェノール樹脂の製造方法
JP7338993B2 (ja) * 2019-03-06 2023-09-05 株式会社クラレ 多孔質炭素および多孔質炭素の製造方法
JP7061640B2 (ja) * 2019-04-16 2022-04-28 フタムラ化学株式会社 活性炭吸着剤の製造方法
WO2020213559A1 (ja) * 2019-04-16 2020-10-22 フタムラ化学株式会社 活性炭吸着剤の製造方法
JP7563145B2 (ja) * 2019-12-05 2024-10-08 ａｒｔｉｅｎｃｅ株式会社 多孔質炭素及びその製造方法
WO2024261472A1 (en) * 2023-06-20 2024-12-26 Yaqrit Limited Porous carbon particles for use in therapy
KR102971111B1 (ko) 2023-09-05 2026-06-02 한국생산기술연구원 열경화성 에폭시 조성물, 이의 경화물 및 용도
CN121925310A (zh) * 2025-03-28 2026-04-24 大阪燃气化学有限公司 麻醉气体吸附剂、麻醉气体吸附过滤器、吸入麻醉系统以及麻醉气体的去除方法
JP7724390B1 (ja) * 2025-03-28 2025-08-15 大阪ガスケミカル株式会社 麻酔ガス吸着剤、麻酔ガス吸着剤の製造方法、麻酔ガス吸着フィルター、吸入麻酔システム、および、麻酔ガスの除去方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004123672A (ja) * 2002-10-07 2004-04-22 Kureha Chem Ind Co Ltd 経口投与用肝疾患治療又は予防剤
WO2011070363A1 (en) * 2009-12-09 2011-06-16 Mast Carbon International Ltd Carbon and its use in blood cleansing applications

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5332637B2 (enExample) * 1973-05-09 1978-09-09
JPS51151693A (en) 1975-06-23 1976-12-27 Eisai Co Ltd Coated bead-like activated carbon for blood purification
JPS5673542A (en) 1979-11-22 1981-06-18 Kureha Chem Ind Co Ltd Adsorbent
JPS5731864A (en) * 1980-08-04 1982-02-20 Teijin Ltd Oral activated carbon microcapsule
RU2177319C2 (ru) * 1999-03-30 2001-12-27 Российская медицинская академия последипломного образования МЗ РФ Способ лечения гиперэндотоксинемии
GB0019417D0 (en) 2000-08-09 2000-09-27 Mat & Separations Tech Int Ltd Mesoporous carbons
JP3522708B2 (ja) 2001-04-11 2004-04-26 呉羽化学工業株式会社 経口投与用吸着剤
EP1407772B9 (en) 2002-10-09 2007-02-21 Kureha Corporation Pharmaceutical composition comprising porous spherical carbonaceous substance and its use for the treatment of renal and liver diseases
CA2504517C (en) 2002-11-01 2008-08-12 Kureha Corporation Adsorbent for oral administration, and agent for treating or preventing renal or liver disease
US7651974B2 (en) 2002-11-01 2010-01-26 Kureha Chemical Industry Co., Ltd. Adsorbent for oral administration
JP2005089306A (ja) * 2003-09-12 2005-04-07 Ajinomoto Co Inc 炎症性腸疾患治療用の経直腸投与製剤
JP4382629B2 (ja) * 2003-10-22 2009-12-16 株式会社クレハ 経口投与用吸着剤、並びに腎疾患治療又は予防剤、及び肝疾患治療又は予防剤
KR101135260B1 (ko) * 2003-10-22 2012-04-12 가부시키가이샤 쿠레하 경구투여용 흡착제, 신질환 치료 또는 예방제 및 간질환치료 또는 예방제
TWI370013B (en) * 2004-04-02 2012-08-11 Kureha Corp Adsorbent for oral administration, and agent for treating or preventing renal or liver disease
TWI370012B (en) 2004-04-02 2012-08-11 Kureha Corp Adsorbent for oral administration, and agent for treating or preventing renal or liver disease
JP2007045775A (ja) 2005-08-11 2007-02-22 Japan Organo Co Ltd 含水活性炭及びその製造方法
DE102005062160A1 (de) 2005-12-19 2007-06-21 BLüCHER GMBH Aktivkohle für die medizinische Verwendung
US8048413B2 (en) 2006-05-17 2011-11-01 Helene Huguet Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules
CA2660883C (en) 2006-10-09 2014-12-09 British American Tobacco (Investments) Limited Carbonising and/or activating carbonaceous material
BRPI0719161A2 (pt) 2006-10-09 2014-02-04 British American Tobacco Co Processos para produzir glóbulos sólidos discretos de material polimérico, para preparar um produto de carbono ativado, e para preparar um produto particulado carbonizado, aparelho para formar glóbulos sólidos discretos de material polimérico, métodos para carbonizar e ativar material carbonáceo, e para preparar carbono ativado, e, forno rotativo.
WO2010138519A2 (en) 2009-05-27 2010-12-02 Ocera Therapeutics, Inc. Use of adsorbent carbon microspheres for the treatment of pruritus
PL2538930T3 (pl) 2010-02-23 2016-11-30 Preparaty do doustnego dostarczania środków adsorbujących do jelita
JP5984352B2 (ja) * 2010-10-12 2016-09-06 フタムラ化学株式会社 経口投与用医薬用吸着剤の製造方法
GB201204696D0 (en) * 2012-03-16 2012-05-02 Ucl Business Plc Therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004123672A (ja) * 2002-10-07 2004-04-22 Kureha Chem Ind Co Ltd 経口投与用肝疾患治療又は予防剤
WO2011070363A1 (en) * 2009-12-09 2011-06-16 Mast Carbon International Ltd Carbon and its use in blood cleansing applications

Also Published As

Publication number Publication date
DK2825181T3 (da) 2020-04-14
IN2014DN07637A (enExample) 2015-05-15
EP2825181A1 (en) 2015-01-21
EP3650031B1 (en) 2026-07-01
MY169093A (en) 2019-02-18
EP2825181B1 (en) 2020-01-08
EA201491690A1 (ru) 2015-02-27
JP6647570B2 (ja) 2020-02-14
NZ631429A (en) 2016-09-30
EA038965B1 (ru) 2021-11-16
AU2013234099B2 (en) 2017-03-30
SG11201405771QA (en) 2014-10-30
JP6293680B2 (ja) 2018-03-14
KR20200096991A (ko) 2020-08-14
KR102142504B1 (ko) 2020-08-07
BR112014022810B1 (pt) 2021-04-13
AU2013234099A1 (en) 2014-10-02
CN104363916B (zh) 2018-09-25
KR20150002675A (ko) 2015-01-07
WO2013136094A1 (en) 2013-09-19
CN104363916A (zh) 2015-02-18
ZA201406989B (en) 2015-12-23
EP3650031A1 (en) 2020-05-13
EP3650031C0 (en) 2026-07-01
US20150064256A1 (en) 2015-03-05
US9844568B2 (en) 2017-12-19
JP2015516373A (ja) 2015-06-11
JP2018111699A (ja) 2018-07-19
GB201204696D0 (en) 2012-05-02

Similar Documents

Publication Publication Date Title
KR102142504B1 (ko) 간질환의 치료 또는 예방용 다공성 탄소 입자
Zhao et al. Nanoparticle-assembled bioadhesive coacervate coating with prolonged gastrointestinal retention for inflammatory bowel disease therapy
Zhong et al. Microalgae‐based hydrogel for inflammatory bowel disease and its associated anxiety and depression
Ding et al. Oral colon-targeted konjac glucomannan hydrogel constructed through noncovalent cross-linking by cucurbit [8] uril for ulcerative colitis therapy
Ma et al. Engineered probiotics enable targeted gut delivery of dual gasotransmitters for inflammatory bowel disease therapy
AU2021206871B2 (en) Gut-selective sequestering agents for the treatment and prevention of autism and related disorders
Wu et al. Natural medicines-derived carbon dots as novel oral antioxidant administration strategy for ulcerative colitis therapy
Li et al. In situ sprayed self‐gelling powder self‐assembled by a pure molecular drug from herbal extract for rapid hemostasis and neuroprotection in traumatic brain injury
Hou et al. Integrated oral microgel system ameliorates renal fibrosis by hitchhiking co-delivery and targeted gut flora modulation
Qian et al. pH/temperature responsive curcumin-loaded micelle nanoparticles promote functional repair after spinal cord injury in rats via modulation of inflammation
Wu et al. Astragaloside IV-loaded biomimetic nanoparticles target IκBα to regulate neutrophil extracellular trap formation for sepsis therapy
US20190142866A1 (en) Porous carbon particles for use in the treatment or prevention of liver disease
Jia et al. Melatonin Protects Against Colistin‐Induced Intestinal Inflammation and Microbiota Dysbiosis
Wang et al. In vitro assessment of berberine-loaded carboxymethyl chitosan hydrogel: A promising antimicrobial candidate for S. aureus-induced bovine mastitis treatment
Chen et al. The postbiotic of hawthorn-probiotic ameliorates constipation by multi-pathway inhibition of PANoptosis in intestinal epithelial cells
Yang et al. Ameliorative effect of melatonin against increased intestinal permeability in diabetic rats: possible involvement of MLCK-dependent MLC phosphorylation
Zheng et al. Calcined lotus leaf-derived carbon dots: enhanced hemostasis, anti-inflammatory, immunomodulatory properties for ulcerative colitis management
EP4731232A1 (en) Porous carbon particles for use in therapy
Sun Stimuli-Responsive Supramolecular Biomaterials for Targeted Treatment of Ulcerative Colitis
Niu et al. Antibacterial efficacy and pharmacokinetics of a poly (mPEG-b-PCEA)–trimethoprim conjugate
CN111265477A (zh) 一种卡络磺钠氯化钠注射液及其制备方法
Tong et al. Synthesis, antibacterial activity, and mechanistic characterization of novel 9-substituted berberine derivatives
Chen Development of Bilirubin-Based Drug Delivery Systems for the Treatment of Inflammatory Bowel Disease

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20200803

Application number text: 1020147029083

Filing date: 20141016

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200902

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20201005

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210813

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220608

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220905

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220906

End annual number: 3

Start annual number: 1

PG1601 Publication of registration